. Author manuscript; available in PMC: 2015 Apr 2.

Published in final edited form as: Support Care Cancer. 2014 Jun 26;23(1):55–59. doi: 10.1007/s00520-014-2326-9

Table 1. Baseline demographics.

Baseline demographics by type of chemotherapy or patients receiving fosaprepitant

	AC (N=99)	Platinum (N=81)	Total (N= 180)	p value
Age at time of chemo				0.0266^a
N	99	81	180
Mean (SD)	53.3 (9.7)	56.4 (13.2)	54.7 (11.5)
Median	55.0	57.0	56.0
Range	(31.0–74.0)	(22.0–77.0)	(22.0–77.0)
Gender				<0.0001^b
Male	2 (2.0 %)	50 (61.7%)	52 (28.9 %)
Female	97 (98.0 %)	31 (38.3 %)	128 (71.1 %)
Ethnicity				0.2069^b
White	91 (91.9%)	77 (95.1 %)	168 (93.3 %)
Black	2 (2.0 %)	0 (0.0 %)	2 (1.1 %)
Asian	0 (0.0 %)	1 (1.2 %)	1 (0.6 %)
Hispanic	3 (3.0 %)	1 (1.2 %)	4 (2.2 %)
Other	3 (3.0 %)	0 (0.0 %)	3 (1.7%)
American Indian	0 (0.0 %)	1 (1.2 %)	1 (0.6 %)
Middle Eastern	0 (0.0 %)	1 (1.2 %)	1 (0.6 %)
Primary cancer diagnosis				<0.0001^b
Breast	98 (99.0 %)	4 (4.9 %)	102 (56.7 %)
Lung	0 (0.0 %)	20 (24.7 %)	20 (11.1 %)
GI	0 (0.0 %)	12 (14.8%)	12 (6.7%)
Reproductive or genitourinary	1 (1.0 %)	15 (18.5 %)	16 (8.9%)
Other	0 (0.0 %)	7 (8.6 %)	7 (3.9 %)
Endo	0 (0.0 %)	6 (7.4 %)	6 (3.3 %)
Head	0 (0.0 %)	17 (21.0%)	17 (9.4%)
Prior history of chemo				<0.0001^b
No	84 (84.8 %)	40 (49.4 %)	124 (68.9 %)
Yes	15 (15.2%)	41 (50.6 %)	56 (31.1 %)
Metastasis				<0.0001^b
Yes	2 (2.0 %)	22 (27.2 %)	24 (13.3 %)
No	97 (98.0 %)	59 (72.8 %)	156 (86.7%)
Corticosteroid use				0.3644^b
No	1 (1.0 %)	0 (0.0 %)	1 (0.6 %)
Yes	98 (99.0 %)	81 (100.0 %)	179 (99.4 %)
Prior use of fosaprepitant				–^b
No	99 (100.0 %)	81 (100.0 %)	180 (100.0%)
Prior use of aprepitant				<0.0001^b
No	98 (99.0 %)	57 (70.4 %)	155 (86.1 %)
Yes	1 (1.0 %)	24 (29.6 %)	25 (13.9 %)

AC anthracycline-cyclophosphamide

Kruskal Wallis

Chi-Square